ARTICLE | Company News
Vernalis, Paul Capital Partners deal
March 15, 2010 7:00 AM UTC
Vernalis completed its previously announced reacquisition of the frovatriptan royalty stream for the acute treatment of migraine from Paul Capital's Paul Capital Healthcare fund for $32.6 million in c...